Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo

Rupani, Neil; Ngole, Mbong Eta; Lee, J. Austin; Aluisio, Adam R.; Gainey, Monique; Perera, Shiromi M.; Ntamwinja, Lina Kashibura; Matafali, Ruffin Mbusa; Muhayangabo, Rigo Fraterne; Makoyi, Fiston Nganga; Laghari, Razia; Levine, Adam C.; Kearney, Alexis S.

doi:10.3201/eid2806.212223

i

Effect of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Vaccination on Ebola Virus Disease Illness and Death, Democratic Republic of the Congo

Supporting Files Public Domain

6 2022
By Rupani, Neil ; Ngole, Mbong Eta ; Lee, J. Austin ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Rupani, Neil ; Ngole, Mbong Eta ; Lee, J. Austin ; Aluisio, Adam R. ; Gainey, Monique ; Perera, Shiromi M. ; Ntamwinja, Lina Kashibura ; Matafali, Ruffin Mbusa ; Muhayangabo, Rigo Fraterne ; Makoyi, Fiston Nganga ; Laghari, Razia ; Levine, Adam C. ; Kearney, Alexis S.
Description:

We conducted a retrospective cohort study to assess the effect vaccination with the live-attenuated recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine had on deaths among patients who had laboratory-confirmed Ebola virus disease (EVD). We included EVD-positive patients coming to an Ebola Treatment Center in eastern Democratic Republic of the Congo during 2018-2020. Overall, 25% of patients vaccinated before symptom onset died compared with 63% of unvaccinated patients. Vaccinated patients reported fewer EVD-associated symptoms, had reduced time to clearance of viral load, and had reduced length of stay at the Ebola Treatment Center. After controlling for confounders, vaccination was strongly associated with decreased deaths. Reduction in deaths was not affected by timing of vaccination before or after EVD exposure. These findings support use of preexposure and postexposure recombinant vesicular stomatitis virus-Zaire Ebola virus vaccine as an intervention associated with improved death rates, illness, and recovery time among patients with EVD.
Subjects:

Animals Ebola Vaccines Ebolavirus Hemorrhagic Fever, Ebola Humans Retrospective Studies Vaccination Vaccines, Attenuated Vesicular Stomatitis Vesiculovirus
Source:

Emerg Infect Dis. 2022; 28(6):1180-1188
Pubmed ID:

35608607
Pubmed Central ID:

PMC9155898
Document Type:

Journal Article
Place as Subject:

Democratic Republic of the Congo
Volume:

28
Issue:

6
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:88f717e6f30987c15a8823fcfb8488988665d9e4e4e33a377695eaeef32ef128
Download URL:

https://stacks.cdc.gov/view/cdc/118174/cdc_118174_DS1.pdf
File Type:

[PDF - 1.45 MB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.